TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10378673

Group type: COMPARATOR
Intervention: Constant rate infusion of HAI FUDR (80 mg/m2/day) and i.v. 5-FU (1200 mg/m2/day) for 5 days every 3 weeks (schedule A)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Chronotherapy with sinusoidal modulation of HAI FUDR (80 mg/m2/day) and i.v. 5-FU (1200 mg/m2/day) for 5 days every 3 weeks (schedule B)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Schedule B (Chronotherapy)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Schedule A (Constant rate infusion)
Number of subjects: 56
Study: 8907090

Group type: EXPERIMENTAL
Intervention: Empirical Bayes methods based on a random‐effects regression model
Number of subjects: 0
Study: 1986037

Group type: EXPERIMENTAL
Intervention: Thiamin supplementation (10 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 6688635

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (650 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen elixir (650 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen tablet (650 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Two commercially available tablet formulations (325 mg each)
Number of subjects: 26
Study: 30380332

Group type: EXPERIMENTAL
Intervention: Psychiatric disclosure
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Facilitators and barriers of disclosure
Number of subjects: 35
Study: 27477485

Group type: EXPERIMENTAL
Intervention: scFOS (5 g d-1) for 4 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: scFOS
Number of subjects: 79
Study: 25615566

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 76

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 76

Group type: COMPARATOR
Intervention: Combination treatment
Number of subjects: 76
Study: 25015368

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Befriending (active comparison condition)
Number of subjects: 0
Study: 22522141

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg/day with probiotics (Enterococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Bacillus coagulans 50 million spores) at a dose of two capsules three times daily (group 1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Norfloxacin with placebo (group 2)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg/day with probiotics (group 1)
Number of subjects: 110
Study: 21141289

Group type: EXPERIMENTAL
Intervention: Chart Card
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 94
Study: 17590511

Group type: EXPERIMENTAL
Intervention: 200 mg levodopa/50 mg benserazide during endurance exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: 200 mg levodopa/50 mg benserazide during rest
Number of subjects: 20
Study: 16304854

Group type: EXPERIMENTAL
Intervention: Clopidogrel Lowplat (drug B) 600 mg (8 tablets) given once
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel Plavix (drug A) 600 mg (8 tablets) given once
Number of subjects: 0
Study: 11943134

Group type: EXPERIMENTAL
Intervention: Erythromycin 600 mg during fasting and 1 g postprandially
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 12‐month and 24‐month groups
Number of subjects: 23
Study: 9805101

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g for 5 days, then 3 g daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Strength training (3 sets of 8 repetitions at 80% of one-repetition maximum, 3 days a week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (placebo) with strength training
Number of subjects: 32
Study: 7714978

Group type: EXPERIMENTAL
Intervention: Polyestradiol phosphate plus ethinylestradiol (80 mg polyestradiol phosphate by intramuscular injection every 4 weeks plus 50 micrograms ethinylestradiol 3 times daily)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (280 mg 2 times daily)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Deferred treatment (surveillance only)
Number of subjects: 285
Study: 3511382

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham exchange
Number of subjects: 29
Study: 27789050

Group type: EXPERIMENTAL
Intervention: Total intervention group (GIT)
Number of subjects: 4236

Group type: EXPERIMENTAL
Intervention: Partial intervention group (GIP)
Number of subjects: 4236

Group type: COMPARATOR
Intervention: Blinded control group (GC)
Number of subjects: 4236
Study: 26945929

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide and albuterol delivered via the Combivent Respimat Soft Mist Inhaler (CVT-R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorofluorocarbon-propelled Combivent metered-dose inhaler (CVT-MDI)
Number of subjects: 0
Study: 24300131

Group type: EXPERIMENTAL
Intervention: Surgical fat-filling procedure (SFFP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-filling group (control)
Number of subjects: 100
Study: 22227638

Group type: EXPERIMENTAL
Intervention: 80 units oxytocin
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: 40 units oxytocin
Number of subjects: 1798

Group type: COMPARATOR
Intervention: 10 units oxytocin (control)
Number of subjects: 1798
Study: 20649032

Group type: EXPERIMENTAL
Intervention: Glargine plus metformin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn plus metformin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 18517112

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg kg(‐1)) and Remifentanil (0.1 microg kg(‐1) min(‐1))
Number of subjects: 120

Group type: COMPARATOR
Intervention: Halothane (1%) and Fentanyl (1.5 microg kg(‐1))
Number of subjects: 120
Study: 18377139

Group type: EXPERIMENTAL
Intervention: Opioid blockade (8 mg naloxone i.v.)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 15026911

Group type: EXPERIMENTAL
Intervention: Single-use disposable laparoscopic instruments (DLI)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Reused disposable laparoscopic instruments (DLI) after high-level disinfection
Number of subjects: 125

Group type: COMPARATOR
Intervention: Single-use DLI
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Reused DLI
Number of subjects: 125
Study: 11414007

Group type: EXPERIMENTAL
Intervention: Attention directed to the local level (more difficult selection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention directed to the global level (less difficult selection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shorter presentations of prime and probe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer presentations of prime and probe
Number of subjects: 0
Study: 9291757

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 micrograms.kg‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8368544

Group type: EXPERIMENTAL
Intervention: 1.5% hyperbaric lidocaine
Number of subjects: 56

Group type: COMPARATOR
Intervention: 5% hyperbaric lidocaine
Number of subjects: 56
Study: 2873107

Group type: EXPERIMENTAL
Intervention: tritoqualine
Number of subjects: 21

Group type: COMPARATOR
Intervention: dexchlorpheniramine maleate (DCPM)
Number of subjects: 21
Study: 30508316

Group type: EXPERIMENTAL
Intervention: Romosozumab followed by Denosumab
Number of subjects: 7180

Group type: COMPARATOR
Intervention: Placebo followed by Denosumab
Number of subjects: 7180
Study: 28830741

Group type: EXPERIMENTAL
Intervention: Fish oil (360mg DHA + 540mg EPA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26332701

Group type: EXPERIMENTAL
Intervention: Hydrocodone‐acetaminophen
Number of subjects: 174
Study: 24500080

Group type: EXPERIMENTAL
Intervention: Implementation intentions for physical activity (experimental condition)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Implementation intentions for an unrelated behavior (control condition)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No treatment (control condition)
Number of subjects: 75
Study: 22151836

Group type: EXPERIMENTAL
Intervention: Mealtime insulin aspart
Number of subjects: 78

Group type: COMPARATOR
Intervention: Bedtime neutral protamine Hagedorn (NPH) insulin
Number of subjects: 78
Study: 20642551

Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride (HCl)
Number of subjects: 189
Study: 17960950

Group type: EXPERIMENTAL
Intervention: Randomised controlled trial (RCT) design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrospective study design
Number of subjects: 0
Study: 15595588

Group type: EXPERIMENTAL
Intervention: 25 microg kg(‐1) alfentanil intravenously
Number of subjects: 82

Group type: COMPARATOR
Intervention: Peripheral nerve blockade using 1 mLkg(‐1) ropivacaine 0.475%
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 12.5 microg kg(‐1) alfentanil intravenously with peripheral nerve blockade
Number of subjects: 82
Study: 11594440

Group type: EXPERIMENTAL
Intervention: Citicoline (1 g/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9520588

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Systemic oestrogen
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Oestrogen for urogenital disorders
Number of subjects: 1035
Study: 7990717

Group type: EXPERIMENTAL
Intervention: Basal periulcer flow measured by laser Doppler fluxometry (LDF)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Circulating blood volume measured by LDF
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Blood velocity measured by LDF
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Maximal Q measured by LDF
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Maximal V measured by LDF
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Maximal U measured by LDF
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Basal values expressed as a percentage of maximal response for Q, V, and U
Number of subjects: 16
Study: 3195780

Group type: EXPERIMENTAL
Intervention: Change of flush solution and pressure monitoring tubing every 24 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Change of flush solution every 24 hours and change of pressure monitoring tubing every 48 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Change of flush solution and pressure monitoring tubing every 48 hours
Number of subjects: 30
Study: 30007054

Group type: EXPERIMENTAL
Intervention: Flurbiprofen spray
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Flurbiprofen-SCTG
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo-SCTG
Number of subjects: 48
Study: 28644115

Group type: EXPERIMENTAL
Intervention: Usual care supplemented by an individually moulded, lightweight, fibreglass heel cast
Number of subjects: 509

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 509
Study: 25953073

Group type: EXPERIMENTAL
Intervention: Fosphenytoin (FOS) 15 mg/kg phenytoin equivalent (PE) administered intravenously
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline placebo (PBO) administered intravenously
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fosphenytoin (FOS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline placebo (PBO)
Number of subjects: 50
Study: 24597457

Group type: EXPERIMENTAL
Intervention: Door-in-the-face technique with two different requesters present during the same interaction
Number of subjects: 160

Group type: COMPARATOR
Intervention: Door-in-the-face technique with two different requesters not present during the same interaction
Number of subjects: 160
Study: 21586792

Group type: EXPERIMENTAL
Intervention: Thin catheter for hysterosalpingography (HSG)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard metal cannula for hysterosalpingography (HSG)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Thin catheter for hysterosalpingography (HSG) during dye injection
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard metal cannula for hysterosalpingography (HSG) during dye injection
Number of subjects: 89
Study: 18316791

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 463

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Combined treatment arms
Number of subjects: 463
Study: 16594764

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12449846

Group type: EXPERIMENTAL
Intervention: Learning disabled children (LD)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal children (Control)
Number of subjects: 71
Study: 10360765

Group type: EXPERIMENTAL
Intervention: ABT-431 (5, 10, 20, 30, and 40 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7585759

Group type: EXPERIMENTAL
Intervention: 200 mg diltiazem
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Titrated diltiazem (200, 300, or 400 mg)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Titrated placebo
Number of subjects: 158
Study: 2037708

Group type: COMPARATOR
Intervention: theophylline 200 mg every 12 hours alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: theophylline 200 mg every 12 hours with mexiletine 150 mg every 8 hours
Number of subjects: 15
Study: 6166800

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg thrice daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pindolol 7.5 mg twice daily
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 17
Study: 31152034

Group type: EXPERIMENTAL
Intervention: Healthcare voucher model (HcV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electronic health card model (eHC)
Number of subjects: 0
Study: 28841451

Group type: EXPERIMENTAL
Intervention: Human reminder call in preferred language
Number of subjects: 963

Group type: COMPARATOR
Intervention: No prior contact (Control)
Number of subjects: 963
Study: 26176605

Group type: EXPERIMENTAL
Intervention: Selective low-dose spinal anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intrarectal local anesthesia (IRLA) plus periprostatic nerve blockade (PPNB)
Number of subjects: 100
Study: 24445560

Group type: EXPERIMENTAL
Intervention: Methadone PCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine PCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 22496893

Group type: EXPERIMENTAL
Intervention: Active cTBS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham cTBS
Number of subjects: 26
Study: 19168521

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled release carvedilol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous aortic flow augmentation device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyroid hormone analogue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-interferon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mid-regional pro-adrenomedullin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dronedarone
Number of subjects: 0
Study: 17538106

Group type: EXPERIMENTAL
Intervention: Isotonic saline (0.9% NaCl)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (7% NaCl)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sterile (hypotonic) water
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nontreatment control
Number of subjects: 60
Study: 15326018

Group type: EXPERIMENTAL
Intervention: Multifaceted EBM educational intervention (1 hospital, 17 medical students and residents)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (2 hospitals, 23 medical students and residents)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Comparison of change scores between intervention and control groups
Number of subjects: 119

Group type: COMPARATOR
Intervention: Survey of internal medicine residents
Number of subjects: 119
Study: 11430963

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg per day
Number of subjects: 6926

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg per day
Number of subjects: 6926

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6926
Study: 9209608

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 67

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 67
Study: 8425624

Group type: EXPERIMENTAL
Intervention: Growth hormone (12 IU/d)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3623678

Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg p.o.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Calcium infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (low sodium diet)
Number of subjects: 9
Study: 31711582

Group type: EXPERIMENTAL
Intervention: Psychosocial validated questionnaire (PCID‐DTO Rios)
Number of subjects: 2815

Group type: EXPERIMENTAL
Intervention: Legislation regarding presumed consent
Number of subjects: 2815

Group type: EXPERIMENTAL
Intervention: Year of study, knowing a donor, and attitude toward ODT
Number of subjects: 2815

Group type: EXPERIMENTAL
Intervention: Interest in attending a talk about ODT
Number of subjects: 2815
Study: 27808012

Group type: EXPERIMENTAL
Intervention: Water-based exercises (n=17)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Land-based exercises (n=15)
Number of subjects: 32
Study: 25527456

Group type: EXPERIMENTAL
Intervention: Single 2-L dose of Moviprep
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Two separate doses of 1 L of Moviprep
Number of subjects: 23
Study: 23355273

Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Internet
Number of subjects: 285
Study: 21855837

Group type: EXPERIMENTAL
Intervention: Prolonged bivalirudin infusion (4-hour infusion after PCI)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Standard bivalirudin infusion (peri-PCI infusion)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Heparin plus abciximab
Number of subjects: 264
Study: 19247742

Group type: EXPERIMENTAL
Intervention: Group A (10 ml 0.5% - 50 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B (10 ml 0.25% - 25 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group C (40 ml 0.0625% - 25 mg)
Number of subjects: 60
Study: 16913337

Group type: EXPERIMENTAL
Intervention: Highly conservative phlebotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized controls
Number of subjects: 0
Study: 15229391

Group type: EXPERIMENTAL
Intervention: High-dose bolus tirofiban (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Abciximab (n = 50)
Number of subjects: 100
Study: 10858175

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 9059096

Group type: EXPERIMENTAL
Intervention: Invos 3100
Number of subjects: 33

Group type: COMPARATOR
Intervention: Critikon 2020
Number of subjects: 33
Study: 8118471

Group type: EXPERIMENTAL
Intervention: Citalopram 60 mg daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 3772579

Group type: EXPERIMENTAL
Intervention: Patients who received letters (RL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients who did not receive letters (NL)
Number of subjects: 0
Study: 3377459

Group type: EXPERIMENTAL
Intervention: Carumonam (1 g every 8 h)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Gentamicin (1 mg/kg every 8 h)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Carumonam
Number of subjects: 52

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 52
Study: 31335570

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 95

Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 95
Study: 28710053

Group type: EXPERIMENTAL
Intervention: Ovarian stimulation plus tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ovarian stimulation plus letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ovarian stimulation
Number of subjects: 0
Study: 25767035

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Moderate-Intensity Training (MIT)
Number of subjects: 28
Study: 23331982

Group type: EXPERIMENTAL
Intervention: Stress training sessions (experimental group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no stress training)
Number of subjects: 26
Study: 21671276

Group type: EXPERIMENTAL
Intervention: Spaced Education (SE) program following the live CME event, consisting of 40 validated questions and explanations covering 4 clinical topics, with repetition intervals of 8- and 16-days based on performance.
Number of subjects: 246

Group type: COMPARATOR
Intervention: Wait-list control group receiving the SE program 18 weeks later.
Number of subjects: 246
Study: 19117887

Group type: EXPERIMENTAL
Intervention: Laronidase (recombinant human alpha-l-iduronidase)
Number of subjects: 45
Study: 16937109

Group type: EXPERIMENTAL
Intervention: Profylin fluoride gel with buffering components (active gel)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Profylin fluoride gel without buffering components (placebo gel)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rinsing with 0.2% NaF
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rinsing with water
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study: 16366128

Group type: EXPERIMENTAL
Intervention: Long-term rehabilitation program (Group A)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard rehabilitation program (Group B)
Number of subjects: 67
Study: 11564854

Group type: EXPERIMENTAL
Intervention: Community-based participatory research interventions
Number of subjects: 0